Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
January 04, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
October 25, 2021 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conference
April 28, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
February 18, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close....
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conferences
February 12, 2021 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2020 Financial Results
July 23, 2020 07:00 ET | FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
March 02, 2020 16:01 ET | FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
November 04, 2019 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer  
October 23, 2019 07:00 ET | FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...